MMA position on DTG after trials identify potential safety concerns for use at the time of conception
Doultegravir (DTG) is a highly effective, tolerable antiretroviral medicine with a high barrier to resistance; in 2015, WHO recommended it...
Read more about MMA position on DTG after trials identify potential safety concerns for use at the time of conception
Civil society key in TRIPS flexibility implementation
Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...
Read more about Civil society key in TRIPS flexibility implementation
Ukraine eyes patent law reform after civil society push on medicines access
Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups...
Read more about Ukraine eyes patent law reform after civil society push on medicines access
Botswana: Creating (radio) waves to show how intellectual property affects us all
BONELA is raising national awareness as to why intellectual property (IP) and access to medicines are relevant for everyone –...
Read more about Botswana: Creating (radio) waves to show how intellectual property affects us all
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Read more about Fixing the broken patent system: From Marrakech and back again
ICASA 2017: Optimal HIV treatment for ALL
As the 2017 International Conference on AIDS and STIs in Africa (ICASA) draws to a close in Abidja, Cote d’Ivoire,...
Read more about ICASA 2017: Optimal HIV treatment for ALL
BLOG: 39 developing countries excluded from optimal HIV treatment – a dangerous oversight or deliberate tactic?
This World AIDS Day (1 December 2017), we’re pleased to have reached a point where more people are set to...
Read more about BLOG: 39 developing countries excluded from optimal HIV treatment – a dangerous oversight or deliberate tactic?
‘Questionable’ patent on key HIV drug is challenged in Brazil
Legal challenge essential to prevent further barriers to optimal HIV treatment in Brazil. ABIA, our campaign partner in Brazil, is...
Read more about ‘Questionable’ patent on key HIV drug is challenged in Brazil
-
BLOG: We want dolutegravir for all, and we want it now
Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published...
Read more about BLOG: We want dolutegravir for all, and we want it now
HIV activists denounce ViiV for denying 3.5 million people access to optimal treatment
Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment...
Read more about HIV activists denounce ViiV for denying 3.5 million people access to optimal treatment